Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VIDEO: Emblem Corp (CVE:EMC) Symbl Brand Leader in Recreational Market
https://midasletter.com/2018/11/emblem-corp-cveemc-symbl-brand-leader-recreational-market/
Sales at OCS, EMC #3 in sales
See on twitter @griz_online
$360k in sales in 10 days.
Vivo # 4
Read more at http://www.stockhouse.com/companies/bullboard?symbol=v.emc&postid=28896142#dUVfqCYmmrSthU8R.99
Grab the paddles , Emblem is showing signs of a pulse ! The paddles are for me .
Emblem and Aphria: A Strategic Relationship in the Making
https://technical420.com/cannabis-article/emblem-and-aphria-strategic-relationship-making
Emblem finalizes agreement to launch Emblem Germany in joint venture with Acnos Pharma
Agreement will see Emblem export to one of the world’s largest legal medical cannabis markets
Emblem Corp. (TSXV: EMC, OTCQX:EMMBF) ("Emblem" or the "Company"), today announced that, through its wholly-owned subsidiary Emblem Cannabis Corporation (“ECC”), it has signed a definitive agreement with German pharmaceutical wholesaler Acnos Pharma GmbH (“Acnos”) in respect to launching a joint venture under the name “Emblem Germany” (the “JV”) for the purpose of exporting Emblem-branded cannabis products from Canada into Germany. The JV – owned 60% by ECC and 40% owned by Acnos – will allow Emblem to commence exporting its products to Germany, with first deliveries expected to be made in mid-2019.
With a population of approximately 82.5 million and federal health insurance coverage for medical cannabis, Germany has created potentially one of the largest legal medical cannabis markets in the world. Subject to all applicable regulatory approvals, Emblem will supply the JV with cannabis oil for sale to German pharmacies, wholesalers and clinical labs for medical purposes.
“Finalizing and signing the definitive agreement with Acnos is a critical first step towards the establishment of a world-class distribution channel that extends internationally to key markets including Germany,” said Nick Dean, President and CEO of Emblem. “Our joint venture capitalizes on Acnos’ significant market knowledge, depth of understanding, and experience as a distributor with a strong track record in the pharma industry. We anticipate incredible demand for medical cannabis in this market and with that comes an opportunity for Emblem to provide physicians, pharmacists and patients with its trusted, high-quality, innovative, and patient-focused products. Emblem is well positioned to begin operations in an important international market.”
Emblem’s new 30,000 sq. ft. Product Innovation Centre, which includes a 5,000 sq. ft. laboratory built to GMP standards, is expected to be online in Q1 2019. This expanded footprint will provide significantly increased oil extraction capacity required for Emblem to meet the expected demands of the German market.
“Emblem’s medical division has positioned itself as an industry leader by innovating and producing high-quality pharmaceutical products,” said Maximillian Claudel, Co-Owner of Acnos. “From our experience, the long view of the German medical market is focused on oil extracts versus combustible products. Emblem’s experience innovating and delivering premium oil products to patients – along with the Company’s imminent growth in extraction capacity – make it an ideal international partner for Acnos.”
The export of products to Germany will be predicated upon Emblem satisfying applicable regulatory requirements for shipping cannabis products to Germany. This includes completion of Emblem’s GMP-certified laboratory in Ontario, followed by receipt of the European Medical Agency GMP certification which is expected to occur in mid-2019. Emblem will also require a Health Canada issued export permit and provisional import status from the German Bundesopiumstelle (Federal Narcotics Bureau) to import medical cannabis products into Germany.
Mr. Dean added, “This milestone further solidifies Emblem’s position as an industry leader in product innovation, branding and securing distribution networks. We are leveraging the Company’s strong medical history to create lucrative, sustainable partnerships that continue to put patients first. This will be achieved by building long-lasting relationships with some of the best partners the industry has to offer.”
About Acnos
Acnos Pharma GmbH is a pharmaceutical wholesaler based in Aachen, Germany. The company’s mission is to supply branded and non-branded medicines to pharmacies, wholesalers and other healthcare companies within the industry. By working closely with medical professionals and multinational manufacturers, Acnos strives for the highest and the latest standards and procedures to ensure the highest level of safety and quality. The quality management system and staff far exceed the industry's regulatory requirements and standards to ensure flawless, traceable and monitored product paths from the manufacturer to the customer.
About Emblem
Emblem is a fully integrated cannabis company focused on driving shareholder value through product innovation, brand relevance, and access to patient and consumer channels. Through its wholly-owned subsidiary Emblem Cannabis Corporation, Emblem is licensed to cultivate, process, and sell cannabis and cannabis derivatives in Canada under the Cannabis Act. Emblem’s state-of-the-art indoor cannabis cultivation facility and Product Innovation Centre is located in Paris, Ontario. Emblem is also the parent company of GrowWise Health Limited, one of Canada’s leading cannabis education services. Emblem trades under the ticker symbol EMC on the TSX Venture Exchange.
For media inquiries, please contact:
Morgan Cates
H+K Strategies
416.413.4649
Morgan.Cates@hkstrategies.ca
For further information contact:
Ethan Karayannopoulos
Investor Relations
Emblem Corp.
647.748.9696
ethank@emblemcorp.com
Alex Stojanovic
Chief Financial Officer
Emblem Corp.
416.923.1331
alexs@emblemcorp.com
https://ih.advfn.com/p.php?pid=nmona&article=78526645
EMC. Wt.a lading point let's get them .2s
Emblem Corp. CEO Nick Dean welcomes Canada-wide adult-use cannabis legalizatio
https://ih.advfn.com/p.php?pid=nmona&article=78481598
There’s buying/trading/accumulating opportunities all over the sector this morning.
EMC/EMMBF—No fear here!
Another day of surprises sure would be appreciated .
Nice day keep them coming!
: )
Emblem Establishes Temporary “Patient Access Investment Fund” to Partially Cover Medical Cannabis Excise Tax
https://ih.advfn.com/p.php?pid=nmona&article=78465322
EMC
HOD close.
More strength ahead.
I have been saying that since its IPO , god I hope you are right ! It is the only dark cloud in my portfolio , and it is so dark .
Fully agree EMC EMC.WT.A GETTING THESE FILLLS
It's GO Time For Emblem Corp.
https://technical420.com/cannabis-article/its-go-time-emblem-corp
A Letter from Emblem’s President & CEO
TORONTO, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV:EMC, OTCQX:EMMBF) ("Emblem" or the "Company") delivers strategic vision to shareholders:
With adult-use legalization only days away, I am incredibly excited to provide an update on Emblem’s progress and plans for the future.
2018 has been a year of enormous change and evolution for the Emblem group of companies. We have made incredible strides and I couldn’t be prouder of the team we’ve assembled. Emblem continues to bring innovative products to market, most recently with the launch of Atmosphere oral sprays, and we’re firmly executing on our three-year strategy.
Most notably, in the third quarter we executed a strategic pivot in our approach to cannabis production, cancelling our capital-intensive production plans, and instead electing to take advantage of the significant wholesale supply capacity coming online industry-wide. This decision positions Emblem to benefit from what we expect to be falling prices in the production segment as commoditization increases. In practical terms this gives Emblem access to ample capacity, while freeing up our capital resources to focus on our passion for innovative value-added products where we already realize higher margin profiles.
Some of my proudest highlights from the past 10 months:
We took the bold step in signing a significant wholesale supply agreement with Aphria Inc., bringing our anticipated aggregate supply to almost 200,000 kg over five years (the “Aphria Supply Agreement”)
We were one of only six LPs to enter into a supply agreement with Shoppers Drug Mart, to help bring our medical products to patients across Canada
We have received provincial approvals to supply the Ontario, Alberta, British Columbia and Saskatchewan adult-use retail markets, with plans to keep growing Canada-wide in 2019
We made investments geared towards return on investment and established supply agreements with Fire & Flower and Starbuds Canada
We announced an agreement to form a joint venture with Acnos Pharma to bring our medical products to Germany, with an anticipated launch in 2019
We made advances in the product development of our extended release tablet in partnership with Canntab Therapeutics Inc.
We announced a partnership with GreenSpace Brands, a highly regarded consumer packaged goods company, to jointly produce CBD-infused health and beauty products as regulations allow
We launched our first adult-use brand, Symbl, which reinforces the core values of the Emblem brand and philosophy
We strengthened our management team with experienced talent from the beverage alcohol and pharmaceutical industries, including recently announcing the appointment of accomplished pharma executive Wayne Kreppner as President of Emblem’s Medical Division
We established a unique partnership with Durham College, through our patient education division GrowWise Health Limited, to educate future business leaders in the cannabis sector
We invested in DriveABLE to help support alternative methods to test cognitive impairment and support responsible use of cannabis products
We successfully delivered our first adult-use cannabis shipments to Ontario and Alberta at full committed quantities
We nearly doubled our active patient count, resulting in more than 5,000 patients now having access to Emblem’s medical cannabis products.
Finally, we have made significant progress on the completion of our new 30,000 sq. ft. Product Innovation Centre with a 5,000 sq. ft. GMP certified laboratory, scheduled to come online in early 2019
Needless to say, it’s been a busy year!
Emblem has continued to zig while the rest of the industry zagged – we’ve firmly repositioned the company to be a market leader in product innovation and branding. As we’ve seen in U.S. states that have legalized cannabis including Colorado, Washington and California, consumer demand has dramatically shifted away from raw cannabis in favour of innovative, convenient and smoke-free cannabis products that meet more consumer preferences.
Despite this, the industry predominantly continues to follow a cultivation-centered business model that requires cultivators to invest tens of millions of dollars into building and operating complex cannabis farming operations. As a result, massive amounts of capital are diverted away from what we believe could be the real drivers of future revenue growth and shareholder value – specifically research, development and commercialization of the next-generation of cannabis products and brands that consumers want. This is where we think that Emblem can differentiate.
Recognizing this new reality, Emblem is boldly charting its own path. Rather than following the pack, we made the bold decision to move away from cultivation and farming by signing the Aphria Supply Agreement and allowing Emblem to invest its energy and resources into developing revolutionary consumer products, building relevant brands and growing effective distribution channels.
Emblem intends to become a leading health and wellness focused consumer packaged goods company, providing the high quality cannabis products to patients and consumers domestically and internationally. To compete in this rapidly evolving industry, focus is critical to success. Emblem intends to leverage core competencies in innovation, marketing and brand development to launch innovative products and brands before our competitors, giving us a strong first-mover advantage in this nascent industry.
We are driven by three goals, focused on delivering the greatest shareholder returns:
To become a best-in-class producer of health and wellness focused products in the cannabis industry, driven by quality, consistency, and innovation.
To define our target market(s), execute within those markets, and become recognized as a ‘best brand’ in each market segment.
To build a business that is financially sustainable and profitable.
It is my belief that in the future, the notion of “production capacity” will be long forgotten in this sector. What will matter is how brands resonate with end users, and ultimately, their market share both domestically and globally. I believe that this brand recognition is likely the greatest opportunity for the sector and where the greatest shareholder value will be achieved.
Our recent supply commitments significantly amplify the value of our established products, brands and distribution. With our award-winning customer care and network of GrowWise cannabis education centres, we are a trusted source of cannabis products and information, and a collaborative industry leader that is committed to promoting responsible use. I believe that Emblem is well-positioned to realize our pioneering vision and meet the changing needs of consumers, patients and healthcare professionals now and into the future.
We’re Emblem and this is just the beginning.
Nick Dean
President & CEO
Emblem Corp.
https://finance.yahoo.com/news/letter-emblem-president-ceo-175120417.html
Emblem to supply British Columbia and Saskatchewan markets with high quality cannabis
Emblem supply to reach four key provinces
TORONTO, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV: EMC, OTCQX:EMMBF) (“Emblem” or the "Company") today announced that its wholly-owned subsidiary, Emblem Cannabis Corporation, one of Canada’s leading licensed producers of medical cannabis, has received approval to supply British Columbia and Saskatchewan with premium cannabis products under Emblem’s adult-use brand, Symbl.
In B.C., Emblem has been approved to supply cannabis to the BC Liquor Distribution Branch (“BCLDB”) – the sole, wholesale distributor of non-medical cannabis for the province that will operate standalone, public retail stores and provide online sales. In Saskatchewan, Emblem has been approved by the Saskatchewan Liquor and Gaming Authority (“SLGA”) to supply cannabis to the province’s private retail market. A curated range of Symbl-branded dried flower strains and premium cannabis oils are expected to be available in both provinces over the coming months.
“B.C. and Saskatchewan are important markets for Emblem’s continued domestic growth plans and we look forward to working with each province as a trusted partner to supply consumers with high-quality cannabis products that will meet their needs now and into the future,” said Nick Dean, CEO, Emblem Corp. “Emblem is focused on building a business for the long-term through product innovation, developing strong brands and enhanced distribution. With supply approvals in place across four key provinces – which also includes Ontario and Alberta – we continue to expand Emblem’s footprint and open up additional markets for our brands and products.”
“Leveraging Emblem’s existing strength in the medical market, we’re excited to introduce consumers in B.C. and Saskatchewan of legal age to Symbl. Symbl was created to offer a thoughtful brand experience for those seeking cannabis for recreational use that fits within a balanced lifestyle,” said Maria Guest, CMO, Emblem Corp. “Symbl is the first of several brands that Emblem intends to create to target a number of diverse consumer segments. As Canadians begin to navigate the new cannabis landscape, we believe that Symbl will become an established source for product information and cannabis education. We look forward to working with both provinces to build the foundation for a safe and responsible marketplace for consumers.”
Emblem has delivered in full its committed quantities to provincial wholesalers in Ontario and Alberta, meeting critical deadlines for the launch of cannabis legalization on October 17, 2018.
About Symbl
Upon legalization for adult-use, Symbl will offer a range of select strains in dried flower and cannabis oil. The line will cater to the full spectrum of Canadians who plan to explore the legal cannabis landscape. Symbl is the first brand in the adult-use cannabis division of Emblem. For more information, please visit www.symbl.ca.
About Emblem
Emblem, through its wholly-owned subsidiary Emblem Cannabis Corporation, is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the Access to Cannabis for Medical Purposes Regulations (ACMPR). Emblem’s state-of-the-art indoor cannabis cultivation facility and research and development laboratory is located in Paris, Ontario. Led by an experienced management team of healthcare executives, accomplished marketing professionals, and cannabis experts, Emblem is focused on driving shareholder value through product innovation, brand relevance, and access to patient and consumer channels. Emblem is also the parent company of GrowWise Health Limited, one of Canada’s leading cannabis education services. Emblem trades under the ticker symbol EMC on the TSX Venture Exchange. For more information, please visit www.emblemcorp.com.
For media inquiries, please contact:
Morgan Cates
H+K Strategies
416.413.4649
Morgan.cates@hkstrategies.ca
For investor inquiries, please contact:
Ethan Karayannopoulos
Investor Relations
Emblem Corp.
647.748.9696
ethank@emblemcorp.com
Alex Stojanovic
Chief Financial Officer
Emblem Corp.
416.923.1331
alexs@emblemcorp.com
https://globenewswire.com/news-release/2018/10/12/1620458/0/en/Emblem-to-supply-British-Columbia-and-Saskatchewan-markets-with-high-quality-cannabis.html
Emblem and Canntab to Commence Clinical Testing of 12-Hour Extended Release Cannabis Tablets
https://ih.advfn.com/p.php?pid=nmona&article=78280582
EMC—GLTA!
Emblem launches Atmosphere, its first oral dose-metered spray
https://finance.yahoo.com/news/emblem-launches-atmosphere-first-oral-105000283.html
EMC—GLTA
EMC.V bullish shift on the weekly!!!
Emblem signs supply agreement with Aphria to purchase up to 175,000 kg equivalents of cannabis products over five years
https://ih.advfn.com/p.php?pid=nmona&article=78242115
EME.V moving nicely here...look for 1.96 test and then we move to 2.78 long term
For the uninformed like myself , what does this tell you about the performance of EMC ?
Emblem Continues To Advance Operations Both Domestic and Abroad
https://technical420.com/cannabis-article/emblem-continues-advance-operations-both-domestic-and-abroad
EMC/EMMBF—GLTA!
Emblem announces proposed investment in Compass Cannabis Clinic, owner of Starbuds Canada
https://ih.advfn.com/p.php?pid=nmona&article=78223313
We have owned it for a long time too loaded the bottom.
My only dog , been stuck here since IPO , first hint of good news in a long time ! Its been Groundhog Day here for a long time now .
lets just say the weekly clouds are clearing after 9 months///stay tuned for percision exits
Please tell us more !
EMC.V having its time..stay tuned for exits
I can personally verify and confirm this. I live and work near Paris and they just built a massive new building on their property there. That’s only one part of the development there. They are constantly building and developing the site.
Emblem signs five-year supply agreement with Compass Cannabis Clinic for Starbuds Canada
https://ih.advfn.com/p.php?pid=nmona&article=78205999
Without a doubt;
EMC/EMMBF is not a scam by any stretch of the word. I have a family member that has visited the Paris Ontario site many times.
He is an engineering contractor and there are/is/has been huge developments/building/renovations taking place over the past year.
I never make recommendations but can catagorically assure all that there is no scam here.
Personally—I’ve been adding/trading/accumulating as I please.
GLTA!
I hope things change , Emblem has been the constant embarrassment to my cannabis family .
Emblem Corp. Is Barreling Ahead Into The Adult Use Market Rollout
https://technical420.com/cannabis-article/emblem-corp-barreling-ahead-adult-use-market-rollout
EMC/EMMBF—GLTA!
EMC.V its about this time This ran
what a run for Emblem.... I do not own any stocks here but on the other hand I do have a shit lots of warrants hahaha
go EMC!
EMC/EMMBF
Just set it and forget it.
No 8 year university education required.
GLTA!
Emblem Corp. Advances Funding for Natura Naturals Production
https://ih.advfn.com/p.php?pid=nmona&article=78126345
EMC/EMMBF—GLTA!
EMC/V going to make a big move here
Emblem Corp. Reports Second Quarter 2018 Financial Results
https://ih.advfn.com/p.php?pid=nmona&article=78118093
Emblem enters into a supply agreement with operator of the Ontario Cannabis Store for high quality, Ontario-grown cannabis
https://ih.advfn.com/p.php?pid=nmona&article=78110192
Anyone see that 52-week low! Top 5 worst Canadian MJ companies on the OTC! Bankruptcy by EOY 2019!!
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
647
|
Created
|
12/07/16
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |